ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.
The NIH has awarded Hesperos Inc. a $2 million dollar research grant to develop an advanced, animal free platform to test the potency of Botulinum Toxin (BoT).
Hesperos Chief Scientist Dr. J Hickman was a featured speaker at Rare Disease Day at NIH discussing how Human-on-a-Chip systems are actively supporting therapeutic development for Rare Diseases. Watch his presentation here.
Development of an Overdose Model doi.org/10.1038/s41598-023-35694-4 Press Release Link to Publication This research provides an accurate way to model overdose in the lab, using human brain cells programmed to respond to many different opioids. Amid an … Read More
Development of a Malaria-on-a-Chip Model doi.org/10.1038/s41598-023-35694-4 Model developed to study Malaria and potential therapeutics Press Release Link to Publication Hesperos scientists have published a groundbreaking study in Scientific Reports, a Nature journal. The publication, titled “Development … Read More
Hesperos Chief Scientist quoted in the Nature Medicine article discussing the state of the field, including rapid advancement with the adoption of the FDA Modernization Act 2.0.
The FDA Modernization Act 2.0 was signed into law eliminating the animal testing mandate in drug discovery.